

Title (en)
SET OF MEANS FOR TREATING A MALIGNANT PATHOLOGY, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE

Title (de)
SET MIT MITTELN ZUR BEHANDLUNG EINER MALIGNEN ERKRANKUNG, EINER AUTOIMMUNERKRANKUNG ODER EINER
INFEKTIONSERKRANKUNG

Title (fr)
ENSEMBLE DE MOYENS POUR LE TRAITEMENT D'UNE PATHOLOGIE MALIGNNE, D'UNE MALADIE AUTO- IMMUNE OU D'UNE MALADIE
INFECTIEUSE

Publication
EP 2152311 A1 20100217 (FR)

Application
EP 08805512 A 20080425

Priority
• FR 2008000598 W 20080425
• FR 0703013 A 20070425

Abstract (en)
[origin: CA2685057A1] Set of means for treating a malignant pathology, an autoimmune disease or an infectious disease, comprising an effector cell which expresses the Fc gamma RIII receptor (CD16) at its surface, and a monoclonal antibody, wherein the affinity of the Fc region of said monoclonal antibody for CD16 is greater than the affinity of the Fc region of polyclonal immunoglobulins for CD16 .

IPC 8 full level
A61K 39/395 (2006.01); **A61K 35/14** (2006.01); **A61K 35/15** (2015.01); **A61K 35/17** (2015.01)

CPC (source: EP KR US)
A61K 35/15 (2013.01 - EP KR US); **A61K 35/17** (2013.01 - EP KR US); **A61K 39/395** (2013.01 - KR); **A61P 1/04** (2018.01 - EP); **A61P 1/16** (2018.01 - EP); **A61P 5/14** (2018.01 - EP); **A61P 7/00** (2018.01 - EP); **A61P 7/06** (2018.01 - EP); **A61P 9/00** (2018.01 - EP); **A61P 17/00** (2018.01 - EP); **A61P 17/06** (2018.01 - EP); **A61P 19/00** (2018.01 - EP); **A61P 19/02** (2018.01 - EP); **A61P 19/06** (2018.01 - EP); **A61P 21/00** (2018.01 - EP); **A61P 21/04** (2018.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 31/00** (2018.01 - EP); **A61P 31/04** (2018.01 - EP); **A61P 31/12** (2018.01 - EP); **A61P 31/14** (2018.01 - EP); **A61P 31/16** (2018.01 - EP); **A61P 31/18** (2018.01 - EP); **A61P 31/20** (2018.01 - EP); **A61P 33/00** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 35/02** (2018.01 - EP); **A61P 37/00** (2018.01 - EP); **A61P 37/04** (2018.01 - EP); **A61P 37/06** (2018.01 - EP); **C07K 16/18** (2013.01 - KR); **C07K 16/2887** (2013.01 - EP US); **C07K 16/34** (2013.01 - EP US); **G01N 33/563** (2013.01 - KR); **C07K 2317/72** (2013.01 - EP US); **C07K 2317/732** (2013.01 - EP US); **Y02A 50/30** (2018.01 - EP US)

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

Designated extension state (EPC)
AL BA MK RS

DOCDB simple family (publication)
FR 2915398 A1 20081031; **FR 2915398 B1 20121228**; AR 066411 A1 20090819; AU 2008257271 A1 20081204; BR PI0804507 A2 20110830; CA 2685057 A1 20081204; CN 101784284 A 20100721; EP 2152311 A1 20100217; IL 201517 A0 20100531; JP 2010525037 A 20100722; KR 20100021405 A 20100224; TW 200902038 A 20090116; US 2010143370 A1 20100610; WO 2008145866 A1 20081204

DOCDB simple family (application)
FR 0703013 A 20070425; AR P080101760 A 20080425; AU 2008257271 A 20080425; BR PI0804507 A 20080425; CA 2685057 A 20080425; CN 200880013210 A 20080425; EP 08805512 A 20080425; FR 2008000598 W 20080425; IL 20151709 A 20091014; JP 2010504791 A 20080425; KR 20097022136 A 20080425; TW 97115222 A 20080425; US 59747109 A 20091023